نتایج جستجو برای: etanercept

تعداد نتایج: 3313  

Journal: :Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2007
C Rubio-Terrés J P Ordovás Baines R Pla Poblador C Martínez Nieto M J Sánchez Garre M A Rosado Souvirón Ana Sierra Muñoz Miriam Sánchez Mateo

OBJECTIVE To analyse the use of health care resources and the associated costs in patients with rheumatoid arthritis (RA) treated with three biological disease-modifying anti-rheumatic drugs (bDMARDs): etanercept, infliximab and adalimumab. METHOD DESIGN observational, retrospective, multicentre study. Length of study: 6 months. TARGET POPULATION patients with RA, who have been undergoin...

2014
Mei Yang Jianchang Chen Jing Zhao Mei Meng John Calvert

The protective role of etanercept in myocardial ischemia/reperfusion is not well understood. The aim of this study was to investigate whether etanercept modulates neutrophil accumulation, TNF-α induction and oxidative stress in an ischemia/reperfusion injured rat heart model. Rats were randomly exposed to sham operation, myocardial ischemia/reperfusion (MI/R) alone, MI/R+ etanercept. The result...

Journal: :The Journal of rheumatology 2010
Philip J Mease J Michael Woolley Amitabh Singh Wayne Tsuji Meleana Dunn Chiun-Fang Chiou

OBJECTIVE To evaluate the effects of etanercept treatment on patient-reported outcomes (PRO) in patients with psoriatic arthritis (PsA). METHODS A 24-week double-blind comparison to placebo was followed by a 48-week open-label phase in which all eligible patients received etanercept. PRO were measured using the Stanford Health Assessment Questionnaire Disability Index (HAQ-DI), the Medical Ou...

2015
KA Papp K Barber R Bissonnette M Bourcier CW Lynde Y Poulin J Shelton J Toole A Vieira M Poulin-Costello

BACKGROUND Topical corticosteroids are used with systemic therapies for treatment of plaque psoriasis, but data from randomized clinical trials to document efficacy of combination therapy are lacking. OBJECTIVE To evaluate efficacy and safety of adding topical corticosteroid therapy from the time that etanercept dosage is reduced from initial label dose [50 mg twice weekly (BIW)] to maintenan...

Journal: :Lancet 2000
P J Mease B S Goffe J Metz A VanderStoep B Finck D J Burge

BACKGROUND Etanercept, a tumour-necrosis-factor inhibitor, has shown efficacy in the treatment of rheumatoid arthritis. Psoriatic arthritis and psoriasis are disease states in which tumour necrosis factor, a proinflammatory cytokine, is present in increased concentrations in joints and in the skin. Therefore, psoriatic arthritis and psoriasis may be appropriate therapeutic targets for etanercep...

Journal: :Modern rheumatology 2009
Naoki Iwamoto Atsushi Kawakami Keita Fujikawa Toshiyuki Aramaki Shin-Ya Kawashiri Mami Tamai Kazuhiko Arima Kunihiro Ichinose Makoto Kamachi Satoshi Yamasaki Hideki Nakamura Munetoshi Nakashima Akinari Mizokami Akiko Goto Takaaki Fukuda Naoki Matsuoka Yukitaka Ueki Toshiaki Tsukada Kiyoshi Migita Fumiko Shoumura Yojiro Kawabe Kazutaka Shibatomi Masanobu Mine Hiroaki Ida Tomoki Origuchi Kiyoshi Aoyagi Katsumi Eguchi

We tried to determine which baseline variables are responsible for remission induction at 6 months in unselected rheumatoid arthritis (RA) patients of Japanese population treated with etanercept. One hundred forty-one patients with RA who were administered etanercept were registered. Thirty-four patients were started on etanercept monotherapy, 60 patients on cotherapy with methotrexate (MTX) (M...

Journal: :Rheumatology 2011
Taunton R Southwood Helen E Foster Joyce E Davidson Kimme L Hyrich Catherine B Cotter Lucy R Wedderburn Richard G Hull Helen E Venning Joy K Rahman Carole L Cummins

OBJECTIVE Since 2004, juvenile idiopathic arthritis (JIA) patients treated with etanercept and/or MTX have been monitored in the British Society for Paediatric and Adolescent Rheumatology Biologics and New Drug Register. Here, we report the duration of etanercept use for the first 5 years of the register and reasons for discontinuation. METHODS Disease subtype and activity, comorbidity, treat...

2015
Xi Chen Debra C. DuBois Richard R. Almon William J. Jusko

Many monoclonal antibodies (mAbs) and other protein drugs have targets usually residing within tissues, making tissue concentrations of mAbs relevant to their pharmacologic effects. Therefore, knowledge of tissue distribution kinetics is important to better understand their pharmacokinetics and pharmacodynamics. The tissue distribution of mAbs is affected by many physiologic factors that may be...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2015
Xi Chen Debra C DuBois Richard R Almon William J Jusko

Many monoclonal antibodies (mAbs) and other protein drugs have targets usually residing within tissues, making tissue concentrations of mAbs relevant to their pharmacologic effects. Therefore, knowledge of tissue distribution kinetics is important to better understand their pharmacokinetics and pharmacodynamics. The tissue distribution of mAbs is affected by many physiologic factors that may be...

2018
Walter P Maksymowych Stephanie Wichuk Maxime Dougados Heather E Jones Ron Pedersen Annette Szumski Lisa Marshall Jack F Bukowski Robert G Lambert

OBJECTIVE To evaluate the impact on structural lesions observed on MRI in the sacroiliac joints (SIJ) at 12 weeks in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving etanercept or placebo in EMBARK (Effect of Etanercept on Symptoms and Objective Inflammation in nr-axSpA, a 104 week study). METHODS Patients were randomised to double-blind etanercept 50 mg/week or pla...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید